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1. Epidemiology 
International epidemiological studies indicate that over the last 50 years there has been 
progressive raise in diabetes incidence. According to International Diabetes Federation (IDF) 
currently there are 284 millions of people affected by diabetes worldwide and IDF prognosis 
predicts that in 2030 this number for all countries and human races will reach 438 million 
which will account for 7.7% of global population (IDF Atlas, 2010). The highest prevalence of 
diabetes is in North America where it reached the level of 10.2% of adult population whereas 
in Europe the prevalence is 6.9% of population aged 20 to 79 years. Particularly worrying is 
constant increase in diabetes incidence of both type 1 (Patterson et al., 2009; Jarosz-Chobot et 
al., 2011) as well as type 2 (D'Adamo & Caprio, 2011) in developmental age population. As a 
consequence of increase in diabetes prevalence there is higher number of patients with 
microangiopathic complications including diabetic retinopathy (DR) in children and youth 
(Cho et al., 2011) and in adults (Rosenson et al., 2011). Chronic complications reduce the 
quality of life and are a main cause of disability. Diabetic retinopathy has become a leading 
reason for blindness and visual impairment in developed countries and is constantly 
increasing (Fong et al ., 2004). Nearly all patients with type 1 diabetes will develop some 
manifestation of DR, whereas in type 2 diabetic patients 80% of insulin- dependent patients 
and 50% of patients not requiring insulin therapy will have DR within 20 to 25 years following 
disease onset (Lamoureux & Wong, 2011). Among younger-onset patients with diabetes, the 
prevalence of any retinopathy was 8% at 3 years, 25% at 5 years, 60% at 10 years, and 80% at 15 
years. The prevalence of proliferative diabetic retinopathy (PDR) was 0% at 3 years and 
increased to 25% at 15 years (National Health and Nutrition Examination Survey, 2006). 
2. Pathomechanism of diabetic retinopathy 
Although there is a high incidence of diabetic retinopathy, its pathogenesis still remains 
enigmatic. Before changes in the eye fundus  become visible in ophtalmoscopic examination or 
fluorescein angiography, in immunohistopathological study there are already visible 
morphological changes in precapillary arterioles, capillaries and venules of diameter less than 
100 µm. In initial stage of development of diabetic retinopathy there is thickening of basal 
membrane of small vessels, its narrowing and closure, disappearance of pericytes, weakening 
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and distension of small vessel walls and, in consequence, formation of microaneurisms and 
endothelial cell proliferation. Additionally, the following take place: functional changes in 
capillaries, increase in their permeability and disruption of blood-retina barrier. As a result of 
enhanced vascular permeability, oedemas and haemorrhages appear in the retina. Moreover, 
the closure of retinal vessels leads to areas with loss of blood flow within retina, which causes 
its chronic ischaemia and hypoxia and subsequent increase in the production of growth factors 
that, in turn, induce angiogenesis, formation of arterio-venous anastomoses and proliferation 
of fibrous tissue within retina and optic nerve disc (Yoshida et al., 2004; Curtis et al., 2009; Roy 
et al., 2010; Lange et al. 2011). It is commonly accepted that hyperglycaemia plays crucial role 
in pathogenesis of diabetic angiopathy (Roy et al., 2010; Kowluru et al., 2010). Hyperglycaemia 
leads to the formation of advanced glycation end products (AGEs) which are durable, 
irreversible and their characteristic feature is to create cross-links between proteins which in 
turn affects flexibility of vessels (Wa et al., 2007; Roy et al., 2010; Yamagishi et al., 2011). It was 
proved that AGEs interaction with receptor for advanced glycation end products (RAGEs) 
plays a key role in development and progression of late diabetic complications (Thomas et al., 
2011; Yamagishi et al., 2011; Zong et al., 2011). In multiple studies investigating diabetic 
retinopathy pathogenesis more and more attention is paid to inflammatory and angiogenic 
factors (Naldini et al., 2005; Maier et al., 2006;  Campa et al, 2010; Praidou et al., 2010).  
 
Fig. 1. The selected factors involved in the development and progression of diabetic 
retinopathy. AGEs - advanced glycation end products, RAGEs - receptor for advanced 
glycation end products, VEGF- vascular endothelial growth factor, IGF-I - insulin like 
growth factor, PLGF - placental growth factor, HGF – hepatocyte growth factor, PEDF - 
pigment epithelium derived factor, bFGF - basic fibroblast growth factor, TGF-ǃ 
transforming growth factor beta, MMPs – metalloproteinases PDGF-platelet-derived growth 
factor , EGF-Epidermal growth factor, Ang-2 - Angiopoietin-2  
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In the eye of a healthy person endothelial cells are mitotically inactive thanks to pro-
angiogenic and anti-angiogenic factors remaining in balance. Healthy organism maintains 
perfect equilibrium between angiogenesis modulators (Carmeliet, 2003; Kvanta, 2006). 
However in the case of hypoxia or inflammation this balance may be shifted towards 
neoangiogenesis (Kvanta, 2006; Campa et al., 2010). Eye angiogenesis is a complicated multi-
stage process in which new vessels are created from existing ones (Kvanta, 2006; Curtis et 
al., 2009). This usually leads to significant loss of vision in patients with type 1 as well as 
type 2 diabetes (Rosenson et al., 2011; Durham & Herman, 2011). Results of studies 
conducted within last ten years proved that eye angiogenesis may involve choroid, cornea 
as well as retina (Kvanta, 2006; Caporali & Emanueli, 2011). During retinal angiogenesis 
newly formed vessels grow into vitreous where they may break and cause haemorrhage or 
retinal detachment. Fig. 1-3 shows three examples of a fundus of the eyes from normal and 
diabetic individuals.  
   
Fig. 2. Fundus photos of eyes from normal and diabetic individuals. 1. Normal fundus of the 
eye. 2. Proliferative diabetic retinopathy with tractional retinal detachment. 3. Diabetic 
retinopathy accompanied by macular oedema, status after argon laser therapy. 
3. Inflammatory and angiogenic factors of diabetic retinopathy 
3.1 Growth factors 
3.1.1 Vascular Endothelial Growth Factor (VEGF) 
VEGF is the most potent factor stimulating physiological and pathological angiogenesis. It is 
a 46-48 kD of molecular weight glycosylated homo-dimer produced by endothelial cells, 
macrophages, CD4 lymphocytes, plasmatic cells, myocytes, megakaryocytes as well as 
neoplasm cells (Ferrara et al., 2003, Ferrara, 2004). VEGF induces new blood vessel 
formation through binding to receptors. The VEGF family encompasses 6 proteins: VEGF-
A,-B,-C,-D,-E and PLGF. Best known and most frequently used clinically is VEGF-A. There 
are also other VEGF isoforms known: VEGF121, VEGF145, VEGF148, VEGF162, VEGF165, 
VEGF183, VEGF189, VEGF206, with different amino acid chain length, ability to bind 
heparin, mitogenic activity and VEGF receptor affinity (Ferrara, 2004; Simó et al., 2006; 
Wirostko et al., 2008). VEGF stimulates proliferation and migration of endothelial cells and 
increases blood vessel permeability (Aiello et al, 1994; Wirostko et al., 2008). Furthermore it 
induces production of tissue collagenase and increases macrophage and monocytes 
chemotaxis. The authors (Matsumoto et al., 2002; Oh et al., 2010; Suzuki  et al., 2011) 
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demonstrated that VEGF increases monocyte chemoattractant protein-1 (MCP-1) mRNA 
expression. VEGF induces MCP-1 most likely through activation of transcription factors 
such as NFκB and AP-1 and signalling pathways dependent and independent from ERKs 
(Mohammad & Kowluru, 2010). It is known that pro-inflammatory protein MCP-1 is a 
potent attractant for monocytes and has been detected in the majority of patients with 
proliferative retinopathy. As it causes monocyte/ macrophage infiltration, it leads to 
vascular abnormalities (Czepluch et al., 2009; Zhang et al., 2009).The hypothesis that 
monocytes / macrophages participate in the pathogenesis of retinopathy is further 
supported by the results (Kataoka et al.,2011). The vitreous macrophages are attracted to the 
pathological vessels induced by retinal ischemia. In children and adolescents with T1DM there 
was a significant increase of VEGF levels in serum, not only in patients with type 1 diabetes 
and non-proliferative retinopathy, but also in patients in whom the ophthalmic examination 
showed no changes in the organ of sight (Chiarelli et al., 2000; Santilli et al., 2002; Zorena et al., 
2007; Myśliwiec et al., 2008). Those findings suggest that VEGF may play  a role in  the 
development of vascular changes within the eye in children and adolescents already in first 
few years of disease when available diagnostic methods can’t detect retinopathic changes. 
Furthermore, in other studies (Zorena et al., 2010) it has been noted that VEGF level has been 
higher in patients with hypertension, retinopathy and nephropathy compared to diabetic 
patients without hypertension although with retinopathy and nephropathy.In addition, there 
were no significant differences in VEGF levels between patients with T1DM group without 
hypertension, but with retinopathy and nephropathy compared to healthy controls group. 
Furthermore, how does hypertension lead to increased production of VEGF in children and 
adolescents with retinopathy is not fully known. It is believed that it is a multidirectional 
process. On one hand it is known that persistent hyperglycaemia leading to the elevation of 
HbA1c levels may lead to the production and accumulation of advanced glycation end 
products. Formation of AGEs promotes production of pro-inflammatory cytokines which may 
further initiate increase of VEGF levels and thus indirectly lead to the development of 
hypertension in T1DM (Gallego et al., 2008; Roy et al., 2010). It was shown that VEGF binds to 
VEGFR-2 receptor at the endothelial cell surface which leads to phosphorylation of 
transcription factors via MAPK (mitogen activated protein kinase) (Suzuma et al., 2001; 
Wirostko et al., 2008). As a consequence, there is increase in expression of adhesive molecules, 
cytokines, chemokines which in turn increase proliferation of endothelial cells and production 
of extracellular matrix with simultaneous impairment of its degradation. This leads to 
progressive fibrosis and closure of vessels’ lumen and subsequently increases blood flow 
resistance. Higher resistance in vascular system results in further raise in VEGF production 
which in turn causes changes in structure and ratio of collagen to elastin which makes blood 
vessels stiffer and leads to increase in blood pressure (Iglesias-de la Cruz  et al., 2002; Kvanta et 
al., 2006; Wirostko et al., 2008). Increased levels of VEGF has been detected in vitreous of adult 
patients with proliferative diabetic retinopathy (Maier et al., 2008; Marek et al., 2010; Lange et 
al., 2011). Moreover, it has been demonstrated that high level of VEGF in vitreous of patients 
with proliferative diabetic retinopathy has been associated with increased VEGF level in 
serum (Maier et al., 2008). The emerging new therapies based on application of anti VEGF 
gave promising results in treatment of proliferative diabetic retinopathy (Adamis et al,. 2006; 
Starita et al., 2007;. Hernández-DaMota et al., 2010; Engelbert et al., 2011). The first drug in this 
group was sodium pegaptanib (Macugen) with anti VEGF165 properties and has been 
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administered intravitreally. Pegaptanib has been used as a treatment of both diabetic macular  
edema (DME) as well as PDR (Adamis et al., 2006;  Querques et al., 2009; Hornan et al., 2010). 
After intravitreal injection of another VEGF-A inhibitor – ranibizumab (registered by FDA in 
June 2006 as a Lucentis) is good antiangiogenic with vision improvement in 95% of patients 
(Jorge et al., 2011; Rosenfeld et al., 2011).  
3.1.2 Insulin like Growth Factor (IGF-I) 
IGF-I is a polypeptide showing high similarity to insulin. Two different forms are 
distinguished: IGF-I and IGF-II. IGF-I circulates in blood in the form of IGF-binding protein 
(IGF-BP), probably inhibiting activity of free IGF. IGF-I is a pivotal growth factor secreted as 
a result of stimulation by human growth hormone. Both in vivo and in vitro studies indicate 
its anti-apoptotic and anti-inflammatory properties (Goes  et al., 1996; Sukhanov et al., 2007; 
Sun et al., 2010). There are reports that IGF-I has protective actions in ischaemic rat kidney 
due to inhibition of inflammatory cytokine production (Goes  et al., 1996) and anti-apoptotic 
in Parkinson disease via inhibition of GSK-3ǃ signalling pathway (Sun et al., 2010). IGF-I 
exerts its protective actions also in central nervous system and cardiomyocytes (Sun et al., 
2010). In premature babies a small concentration of IGF-I is a risk factor of retinopathy of 
prematurity (Pérez-Muñuzuri et al., 2010). IGF-I deficiency after birth may play a role in 
development and deterioration of neurological deficiencies in premature babies (Lofqvist et 
al., 2006). On the other hand in children and youth with T1DM and microangiopathy IGF-I 
levels have been found to be lower compared to group of patients without microangiopathy 
(Peczyńska et al., 2004). Furthermore, IGF-I levels were lowest in children with T1DM for 
over 10 years. Interestingly, the same group of children had raised VEGF levels in serum 
and the longer the duration of the disease, the higher were the levels (with maximum levels 
in patients with diabetes for over 10 years) (Chiarelli  et al., 2000; Santilli  et al., 2001; 
Peczyńska et al. 2004; Zorena et al., 2009). Also much lower IGF-I concentrations were found 
in adolescents with microangiopathy compared to diabetic patients without complications 
and healthy children (Wedrychowicz et al., 2005). However, IGFBP-1 levels in serum were 
much higher whereas IGFBP-3 were lower in patients with microangiopathy compared to 
those without complications. Thus circulating IGFBP-1 may play a role in development of 
diabetic complications while IGFBP-3 may be protective (Kielczewski et al., 2011). In 
adults with PDR, levels of IGF-I and VEGF in vitreous were significantly higher than in 
control group (Simo et al., 2002; Poulaki  et al., 2004; Hartnett et al., 2009). Surprisingly 
there were no differences in levels of both factors in serum in each group. This effect 
could be explained by two mechanisms: higher concentration of IGF-I binding protein 
(IGFBP’s) in vitreous may neutralize the increased IGF-I production or may lower the  
production of free IGF-I in tissues of diabetic patients  (Simo et al., 2002). Additional 
evidence supporting IGF-I in PDR result from use of IGF-I inhibitors. Somatostatin and 
octreotide, a somatostatin analogue, inhibited IGF-I receptor (IGF-1R) phosphorylation 
and decreased VEGF production (Sall et al. 2004). Systemic inhibition of IGF-I signalling 
in a relevant animal model with a receptor-neutralizing antibody, or with inhibitors of PI-
3 kinase (PI-3K), c-Jun kinase (JNK), or Akt, suppressed downstream signalling pathways, 
VEGF expression, ICAM-1 levels, leukostasis, and BRB breakdown. Intravitreal 
administration of IGF-I increased retinal factors AKT, JNK, HIF-1alpha, NF-κB, AP-1 
activity, and VEGF levels. Haurigot et al., 2009 demonstrated that high intra-ocular 
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concentration of IGF-I in retina is sufficient to activate processes leading to disruption of 
blood-retina barrier and increase in vascular permeability as a consequence of high 
expression of IGF-I in retina. 
3.1.3 Placental Growth Factor (PLGF) 
PLGF is a homodimer protein belonging to VEGF family, showing structural similarity to 
VEGF-A. Three PLGF isoforms have been described (PLGF-1,-2,-3). Those isoforms do not 
interact with VEGFR-2 but they bind to VEGFR-1 (Christinger et. al., 2004). PLGF has been 
recently isolated as a factor, stimulating neovascularization. Over the last decade, the 
direct or indirect pro angiogenic effect of PLGF was demonstrated during ischaemia, 
inflammation and wound healing. There are controversies regarding the pro-angiogenic 
activity of placental growth factor in diabetic retinopathy. In the eye, loss of PLGF does 
not hamper retinal development (Feeney et al., 2003) but impairs choroidal 
neovascularization (Rakic et al., 2003). Intravitreal injections of PLGF prevent oxygen-
induced retinal ischaemia, without inducing neovascularization (Campochiaro et al., 
2006). In animals׳ retinal cells only small amounts of PLGF have been detected. However, 
increased levels have been detected in eyes affected by advanced neovascularization in 
retina (Khaliq et al., 1998; Miyamoto et al., 2007).  
3.1.4 Hepatocyte Growth Factor (HGF) 
HGF is a pleiotropic factor derived from mesenchymal tissue regulating growth and 
migration of various cells. HGF is synthesized mainly in liver but also in lungs, kidney, 
smooth muscles and corneal  endothelial cells (Stoker et al., 1987). It is secreted as a single 
chain precursor which is activated by proteolytic cleavage. Simó et al., 2006 have detected 
increased concentrations of both HGF as well as VEGF in vitreous of patients with PDR 
compared to patients with diabetes but without complications and healthy control group. 
However, they have not demonstrated relevant correlation between HGF and VEGF. 
Yoshida et al., 2010 investigating levels of angiopoietin-2 , HGF, bFGF, PDGF, TIMP-1 and 
TIMP-2 in the vitreous body of PDR patients before and after vitrectomy has shown a 
marked decrease of HGF as well as angiopoietin-2 levels in the vitreous body of PDR 
patients after vitrectomy.  
3.1.5 Pigment Epithelium Derived Factor (PEDF) 
PEDF also known as serpin F1 (SERPINF1), is a multifunctional secreted protein that has 
anti-angiogenic and neurotrophic functions. Found in vertebrates, this 50 kD protein holds 
promise in the treatment of such conditions as heart disease, cancer and choroidal 
neovascularization (Filleur et al., 2009). PEDF is secreted by many retinal cells including 
Müller cells, endothelial cells, pericytes, and pigment epithelium cells of retina (Doll et al., 
2003; Barnstable et al., 2004; Tombran-Tink et al., 2010). Studies conducted on PEDF 
depleted mice, showed that lack of this gene results in serious abnormalities in both, cell 
differentiation as well as in retinal  morphology (Doll et. al., 2003). In 2003 the first 
hypothesis emerged that PEDF may hamper angiogenesis by direct reduction of  VEGF gene 
expression (Yamagishi et al., 2003). Most recent data confirm also that PEDF has direct effect 
on vascular endothelial growth factor receptor 1 (VEGFR-1) by increasing g-secretase 
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complex activity (Cai et al., 2011). Activation of g-secretase leads directly to proteolytic 
cleavage within VEGFR-1 and C-end domain of receptor is removed which subsequently 
migrates from cell membrane into cytosol (Cai et al., 2006; Cai et al., 2011). Additionally, 
PEDF inhibits production of reactive oxygen species (ROS) and MCP-1 and furthermore, it 
neutralizes negative effects of AGE (Inagaki et al., 2003). Other studies suggest that 
transcription factor, NF-κB and Fas ligand and its receptor play a role in PEDF mechanism 
of action. Volpert et. al. 2002, proved that anti-FasL antibodies and application of inhibitors 
hampers PEDF action. PEDF may equally prevent cell apoptosis by activation of 
transcription factor NF-κB, as well as lead to programmed cell deaths via increasing Fas 
ligand expression (Volpert et al., 2002). Studies (Cai et al., 2006) have demonstrated that 
PEDF used in bovine retinal microvascular endothelial cells culture (BRMECs) did not affect 
their migration and formation of primary vessel canals. However, when an addition of 
PEDF had been preceded by application of VEGF then this factor reduced significantly 
proliferation and endothelial cells migration induced by VEGF. Studies evaluating the 
antiangiogenic properties of PEDF have also shown that exerts a modulating effect on the 
formation of new retinal blood vessels and promote angiogenesis in hypoxia (Barnstable et 
al., 2004; Elayappan et al., 2009; Subramanian  et al., 2011). 
3.1.6 Basic fibroblast Growth Factor (bFGF) 
Fibroblast growth factors, or FGFs, are a family of growth factors involved in wound 
healing, embryonic development, and angiogenesis.  There are two FGF distinguished: 
acidic (aFGF) and basic (bFGF), the latter being attributed to play the most significant role in 
angiogenesis. This factor has an ability to directly activate endothelial cells, it also affects 
proliferation, migration of endothelial cells and fibroblasts, induces proteolytic enzymes and 
synthesis of fibronectin, collagen, proteoglycans and hyaluronic acid (Shi et al., 2011).  
Synthesis of bFGF takes place in retina cells as well as in cornea and is activated by 
inflammation or a local injury (Polykandriotis et al., 2011). It has been suggested that bFGF 
exerts its paracrine effects on the eye by inhibition of apoptosis. Other studies have 
demonstrated that  beta-FGF works via two pathways a calcium independent FGFR1 
through PI 3-K, P70(S6K) and Akt to increased VEGF from the RPE and a calcium 
dependant FGFR2. The inhibition of those two pathways suppresses bFGF-induced 
choroidal endothelial cells proliferation (Rosenthal  et al., 2005). Deissler et al., 2011, have 
discovered that VEGF165 but not bFGF is mainly responsible for changes in cell 
permeability observed in retinal endothelium.  
3.1.7 Transforming Growth Factor beta (TGF-β) 
TGF-ǃ is a member of transforming growth factor family which has immunomodulatory 
function. It is secreted primarily by monocytes, macrophages, lymphocytes, and dendritic 
cells. This cytokine takes part in angiogenesis, stimulates synthesis and degeneration of 
extracellular matrix proteins, regulates induction of apoptosis and stimulates proliferation 
of mesenchymal cells. 
TGF-ǃ exists in three isoforms coded by different genes ǃ1, ǃ2, ǃ3; best known is TGF- ǃ1  
(Bertolino et al., 2005; Orlova et al., 2011) . TGF-ǃ is believed to be the most important ligand 
in the pathogenesis of fibrotic diseases in the eye. Such ocular fibrotic diseases include 
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scarring in the cornea and conjunctiva, fibrosis in the corneal endothelium, post-cataract 
surgery fibrosis of the lens capsule, excess scarring of tissue around the extraocular muscles 
in the strabismus surgery and proliferative vitreoretinopathy (Saika et al., 2009; Sumioka et 
al., 2011; Hills et al., 2011). Those properties of TGF-ǃ are confirmed in animal models 
(Yingchuan et al., 2010; Kowluru et al., 2010) as well as in patients with diabetic retinopathy 
(George et al., 2009; Abu El-Asrar et al., 2010). It is believed that TGF-ǃ plays a role in 
pathogenesis of diabetic retinopathy via hyperglycaemia and inflammation. Kowluru et al., 
2010 have reported that both the duration of the initial exposure to high glucose, and normal 
glucose that follows high glucose, are critical in determining the outcome of the alterations 
in the inflammatory mediators such as IL-1 beta, NF-kB, VEGF, TNF-ǂ including with TGF-
ǃ in retinal. 
3.1.8 Angiogenin 
Angiogenin is a small protein that is implicated in angiogenesis. Angiogenin mRNA 
expression is detectable in epithelial cells, fibroblasts and blood cells (Tello-Montoliu et al., 
2006). Higher level of angiogenin was observed in serum in children and adolescents with 
non-proliferative retinopathy as compared to the group of children and adolescents without 
DR (Chiarelli et al., 2002; Raczyńska K et al., 2008). Maier et al., 2006 have revealed that 
angiogenin level has been increasing in the vitreous in diabetic patients. Nevertheless it is 
suggested that the increased level was an effect of blood-retina barrier disruption and 
leakage of growth factors from blood vessels into eye (Maier et al., 2006). Lower levels of 
serum angiogenin was demostrated in patients with type 2 diabetes (Siebert et al., 2007; 
Siebert et al., 2010). Lower level of angiogenin but higher VEGF were found also in the 
vitreous of patients T1DM with PDR (Marek et al., 2011). 
4. Cytokines 
4.1 Interleukin 6 (IL-6) 
Interleukin 6 has been well known as a pro-inflammatory cytokine. However, there is an 
increasing number of reports about its anti-inflammatory character (Sanchez et al., 2003; 
Sappington et al., 2006; Nandi et al., 2010). In vitro in presence of increased pressure and 
injury resulting from ischaemia, IL-6 inhibited apoptosis of retinal ganglion cells (Sanchez et 
al., 2003; Sappington et al.,2006). On the other hand (Dace et al., 2008) M1 macrophages 
prevented  neovascularisation within retina due to high secretion of IL-6, IL-12 and IL-23. 
Although, majority of reports confirm its negative role in the onset and progression of 
diabetic retinopathy (Noma et al., 2009; Funk M et al., 2010; Koleva-Georgieva et al., 2011). 
IL-6 is produced mainly by macrophages, monocytes, lymphocytes T and B, while in the 
eye IL-6 is produced by keratocytes, Müller cells, pigmented epithelium, corneal 
epithelium, iris and ciliary body (Yoshida et al., 2001). IL-6 secretion is activated by 
hypoxia, AGEs, and PKC (protein kinase C) (Giacco & Brownlee, 2010; Adamiec-Mroczek 
et al., 2010; Lange et al., 20011). In children and adolescents with diabetic retinopathy, 
higher levels of IL-6 were demonstrated in serum (Lo Hui-Chen et al., 2004; Zorena et al., 
2007; Myśliwiec et al., 2008 , Bradshaw et al., 2009). A significant increase in the level of 
IL-6 was found in PDR patients compared to NPDR and healthy children. Authors 
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recorded significant gradation in the IL-6 increase when comparing healthy children, 
children with T1DM without abnormalities in the eyes, and diabetic children with non 
proliferative diabetic retinopathy. Higher IL-6 and TNF levels in diabetic children are 
attributed to worse metabolic balance and chronic inflammation (Zorena et al., 2007; 
Myśliwiec et al., 2008). Apart from IL-6 influence on the  set and progression of diabetic 
retinopathy in young patients with diabetes, higher levels of VEGF and C-reactive protein 
were also found (Coulon at al., 2005; Zorena et al., 2007). Coulon et al., discovered in their 
studies that children with long standing diabetes and retinopathy as well as nephropathy 
had five times higher levels of CRP than patients with diabetes but without complications 
(Coulon et al., 2005). Authors concluded that high level of pro-inflammatory cytokines in 
long standing diabetes is a result of ongoing inflammatory process. In inflammatory 
conditions IL-6 levels in serum may increase even 100 times, therefore IL-6 is regarded as 
an early and sensitive but non-specific indicator of inflammatory process affecting the 
organism (Abrahamsson et al, 1997).  High IL-6 levels have been observed also in patients 
with type 2 diabetes and retinopathy as compared to patients without retinopathy (JH Lee 
et al., 2008; Goldberg., 2009). Also in aqueous from eyes with diabetic macular edema 
(Funk et al. 2010) found to be significantly increased IL-6 and VEGF. When patients were 
given bevacizumab, it was noted that VEGF levels dropped below physiological levels. 
Oh et al., 2010, demonstrated positive correlation between the aqueous levels of IL-6 and 
macular thickness indicating that IL-6 may play a central role in the development of 
diabetic macular edema. Other studies concerned the increased levels of IL-6, TNF, ET-1 
vWF, sE-selectin in vitreous detected in patients with type 2 diabetes and PDR (Adamiec-
Mroczek et al., 2010). Furthermore, authors noted correlation between TNF-ǂ, ET-1 and 
HbA1c suggesting that there is close relation between metabolic equilibrium and 
inflammatory factors in T2DM patients. Thus, those studies support pro-inflammatory 
and proangiogenic role of IL-6. 
4.2 Interleukin 10 (IL- 10) 
Several recent studies reported that local IL -10 production may lead to angiogenesis in 
retina. Studies demonstrated that IL-10 may polarize macrophages in proangiogenic 
direction (Apte RS., 2006, Kelly et al., 2007, Dance et al., 2008). In macrophages of 
C57BL/6 mice with induced retinopathy, there has been significantly higher 
proangiogenic cytokine gene expression. This hasn’t been found in macrophages of mice 
with IL-10 -/- phenotype (Dace et al., 2008). In children and adolescents with long-
standing type 1 diabetes more than 60% of patients with symptoms of diabetic 
retinopathy showed no activity of this cytokine in serum. IL-10 levels analysis in group of 
children with T1DM and various grades of diabetic complications in the eye suggests that 
higher secretion of IL-10 may protect from late complications (Myśliwiec et al., 2006). 
Also, there were no significant differences in the IL-10 levels in the vitreous of patients 
with proliferative retinopathy as compared to those without PDR (Hernandez et al., 2005). 
However in T2DM patients, IL-10 was progressively lower with more advanced 
retinopathy (JH Lee et al., 2008). Suzuki et al., 2011 demonstrated higher levels of IL-10 as 
well as positive correlation between IL-10 and VEGF in patients with PDR compared to 
those with central retinal vein occlusion (CRVO). 
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4.3 Interleukin 12 
Interleukin 12 (IL 12) has been described initially as a factor stimulating natural cytotoxic 
cells and causing maturation of cytotoxic lymphocytes. Under physiological circumstances it 
is produced mainly by macrophage, dendritic cells, keratinocytes, granulocytes, and mast 
cells (Trinchieri, 1998).  In vivo, it was demonstrated that IL-12 is a potent antiangiogenic 
cytokine and this effect is mediated through interferon-Ǆ (Voest et al., 1995). Few studies 
conducted in recent years indicate that IL-12 does not affect per se  endothelial cells,  but just 
by IFN-Ǆ (Voest et al., 1995). This in turn regulates production of second line chemokines via 
induction of protein (IP)-10 being recognized as the most important mediator for IL-12 in 
angiogenesis activation (Sgadari et al., 1996). Furthermore, another report suggests that 
inhibition of IL-12 production may be mediated by natural killer cells (NK) (Ghiringhelli et al., 
2006). A significantly lower IL-12 level but higher TNF and VEGF levels were found in a group 
of children and adolescents with diabetes and NPDR as compared to a group of patients 
without DR (Zorena et al., 2007). Another study (Zorena et al., 2008) reported imbalance 
between pro and antiangiogenic factors in serum of children and adolescents with long term 
T1DM. This imbalance was demonstrated between TNF-ǂ and IL-12. It has been observed that 
patients who had both low TNF-ǂ and IL-12 levels did not develop diabetic complications like 
retinopathy or nephropathy. However, when patients had high level of TNF-ǂ and absent IL-
12 they developed microangiopathic complications. Shift in balance towards TNF-ǂ promotes 
late diabetic complications. Loss of equilibrium between pro and antiangiogenic actions of 
TNF-ǂ and IL-12 underpins late diabetic complications. Applied monoclonal antibody against 
p40 subunit of IL-12 – Uteskinumab gave positive results in a patient with Crohn’s disease 
(Sansó Sureda et al., 2011). 
4.4 Tumor Necrosis Factor alpha (TNF-α) 
TNF-ǂ is one of most important inflammatory cytokines. It is produced primarily by 
monocytes and macrophages on which it exerts its endo-, para- and autocrine actions. It 
stimulates cytotoxic properties of monocytes and macrophages and simultaneously is a 
mediator of cytotoxicity. Its biological effects depends strongly on quantity and intensity of 
TNF-ǂ secretion. Apart from taking part in inflammatory processes it also plays important 
role in neovascularisation (Wilson &Balkwill, 2002). TNF-ǂ exerts versatile effects due to its 
ability to induce synthesis of other cytokines functionally related to TNF-ǂ, extracellular 
matrix proteins, monocyte and fibroblast chemotaxis modulation and also influences the 
expression of adhesive molecules in retinal vessels (Doganay et al.,2002; Naldini & Carraro, 
2005). Teflon implants soaked in 3.5 ng TNF-ǂ and implanted into rat cornea caused a 
visible growth of new blood vessels after 7 days (Fajardo et al., 1992). A similar effect was 
achieved on  chicken embryo membranes (Hooper et al., 2005). However, (Patterson et al., 
1996) showed an antiangiogenic action of TNF-ǂ using human endothelial cells. The authors 
showed that incubation of those cells with known proangiogenic factor VEGF for 24h 
augmented their proliferative activity more than two fold, whereas 12h pre-incubation 
abolished this effect. However, TNF-ǂ alone revealed a weak cytotoxic effect towards 
endothelial cells. Inhibition of endothelial cell proliferation by TNF-ǂ was associated with 
reduction in VEGFR-2 (KDR/Flt-1) receptor mRNA transcription level which depends on 
dose and the duration of cytokines. Low concentrations of TNF-ǂ can trigger signalling 
pathways through p55 and p75 receptor, but in high concentrations only through p55 (Bigda 
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et al., 1994). In young patients with newly diagnosed diabetes increased activity of TNF-ǂ 
has been demonstrated (Myśliwiec et al, 2006). High levels of TNF-ǂ have been detected also 
in type 1 diabetic children and adolescents with non-proliferative retinopathy (Myśliwiec et 
al, 2006, Zorena et al. 2007). TNF-ǂ may become a relevant indicator of development and 
risk of diabetic retinopathy. Similar observations were made in adult patients with PDR 
(Gustavsson et al., 2008; Koleva–Georgieva et al., 2011). Levels of TNF-ǂ in vitreous of Type 
2 diabetic patients with PDR were higher than those found in control group. Furthermore a 
correlation between TNF-ǂ and HbA1c  is observed,  suggesting that there is a close relation 
between glycaemic control and inflammatory factors in T2DM patients (Adamiec-Mroczek 
et al., 2008; Lee JH, 2008). TNFRI and TNFRII receptors’ levels in vitreous of patients with 
PDR and proliferative vitreoretinopathy were much higher than in patients with perforation 
in macula (Limb et al., 2001). Attempts are being made to block TNF-ǂ actions with 
monoclonal antibodies (Sfikkakis et al., 2010; Giganti et al., 2010; Biswas et al., 2010). In 
randomized studies, the intravenous use of infliximab has improved visual acuity in 
patients with diabetic macular edema (DME) (Sfikakis et al., 2010). 
Etanercept is a soluble TNF-ǂ receptor that acts as competitive inhibitor blocking effects of 
TNF-ǂ binding to cells. Etanercept reduced leukocyte adherence in retinal blood vessels of 
diabetic rats for 1 week as compared to control. Etanercept did not reduce retinal VEGF 
levels, but it inhibited blood-retinal barrier breakdown and NF-κB activation in the diabetic 
retina (Joussen et al., 2002; Zheng et al., 2004). 
5. Adipocytokines 
5.1 Leptin 
Leptin was discovered as a first adipocytokine in 1994 (Zhang Y et al., 1994). Team of 
researchers (Ates et al., 2008) have found relationship between leptin and retinal vein 
occlusion. The authors suggest that leptin may play a role in pathogenesis of retinal vein 
occlusion probably by influencing vessel wall homeostasis. In diabetes, leptin may affect 
angiogenesis process by induction of vascular endothelial growth factor (VEGF) and 
suppression of pigment epithelium derived factor (PEDF) and also production of intracellular 
reactive oxygen species (ROS) in retinal vascular endothelial cells. (Gariano et al. 2000, 
Yamagishi et al., 2003). However, in other studies the authors reported no association between 
leptin and the development and progression of retinopathy (Sari et al., 2010). 
5.2 Adiponectin 
Adiponectin is a 28 kD protein and its structure is similar to TNF-ǂ, collagen VIII and IX and 
C1q molecule of complement. As demonstrated in vitro adiponectin exerts antyaterogenne, 
by inhibiting the adhesion of monocytes to endothelial cells and the transformation of 
macrophages into foam cells (Diez & Iglesias, 2003; Tan et al., 2004; Abi Khalil et al., 2011). 
Zhou et al., 2011 demonstrated that adiponectin hampers monocytes adhesion to endothelial 
cells in blood vessel walls by reduction in adhesive protein expression. The study also 
reported that adiponectin inhibits macrophages transformation into foam cells, reduces 
smooth muscle proliferation, increases NO synthesis and stimulates angiogenesis. Several 
studies present adiponectin as an anti-inflammatory cytokine (Matzuzawa et al., 2005; 
Goldberg et al., 2009; Zhou et al., 2011). In vitro studies revealed that TNF-ǂ inhibits 
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adiponectin gene expression through inhibition of nuclear factor NFκB, which is activated 
by adiponectin. Increasing insulin resistance and growth of adipose tissue increases TNF- 
alpha expression leading to a decrease of adiponectin concentration (Savino  et al., 2008). 
Additional studies have shown that adiponectin directly stimulates the production of IL10 
by macrophages and decreases the production of proinflammatory cytokines TNF-ǂ and IL6 
(Wulster-Radcliffe et al., 2004, Kumada et al., 2004, Kollias et al., 2011, Zhou et al., 2011). 
Adiponectin inhibits adhesive molecules expression in endothelial cells and also production 
of cytokines in macrophages thus reduces the inflammatory process which is present in 
early stages of atherosclerosis and microangiopathy (Diez & Iglesias, 2003; Goldberg et al., 
2009). Increase in adiponectin level in serum is thought to be a response to endothelium 
damage (Schalwijk et al., 2006; Goldberg et al, 2009).Correlation was found between severity 
of diabetic retinopathy and adiponectin in patients with T1DM  and T2DM (Frystyk  et al., 
2005; Zietz et al., 2008; Kato et al., 2008). 
6. Chemokines 
6.1 Stromal Cell-Derived Factor (SDF-1) 
SDF-1 is a small cytokine of the chemokines family (C-X-C motif) or a ligand 12 (CXCL12). 
SDF-1 plays an important role in the angiogenesis by recruiting endothelial progenitor cells 
from bone marrow (Unoki et al, 2010). In the animal model it has been shown that VEGF, 
SDF-1 alpha and CXCR-4 all play part in the development of diabetic retinopathy. An 
increase in SDF-1 alpha expression has been observed, and it correlated with the duration of 
the disease(Lin et al., 2009) as well as with the level of pro-inflammatory cytokines  IL-6 and 
IL-8 (Otsuka et al, 2010). An increase in SDF-1 concentration in the vitreous has been 
observed also in patients with proliferative retinopathy, the more pronounced, the more 
acute had been the disease course (Meleth et al., 2005; Chen et al., 2008).  
6.2 Monocyte Chemotactic Protein-1 (CCL2/MCP-1) 
Chemokine (C-C motif) ligand 2 (CCL2) is a small cytokine belonging to the CC chemokine 
family that is also known as monocyte chemotactic protein-1 (MCP-1) and small inducible 
cytokine A2. CCL2 is a monomeric polypeptide, with a molecular weight of approximately 
13kD (Yoshimura & Leonard.,  1992). The cell surface receptors that bind CCL2 are CCR2 
and CCR4 (Xia & Sui.,2009). MCP-1, as well as its interaction with CCR2, plays a pivotal role 
in mediating persistent mononuclear phagocyte infiltration that leads to chronic 
inflammatory (Romagnani et al., 2004). Inhibition of CCL2-CCR2 signalling blocks the 
recruitment of inflammatory monocytes, inhibits metastasis in vivo and prolongs the 
survival of tumour-bearing mice (Qian et al., 2011). Also, MCP-1 has been recognized as an 
angiogenic chemokine (Strieter et al.,2005). In vivo angiogenesis assays showed that MCP- 
1-induced angiogenesis was as potent as that induced by vascular endothelial growth factor 
(VEGF). The angiogenic effect of MCP-1 was completely inhibited by a VEGF inhibitor, 
suggesting that MCP-1-induced angiogenesis is mediated through pathways involving 
VEGF (Kim et al., 2005). In young patients with long term diabetes and microangiopathy 
levels of CCL2/MCP-1 were higher than in those without microangiopathy (Zorena et al., 
2010). The authors suggest active role of this chemokine in onset and development of 
diabetic retinopathy. Increased level of CCL2/MCP-1 was higher also in the vitreous of 
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adult patients in PDR. (Hernandez et al., 2005; Abu El-Asrar et al., 2006). The aqueous levels 
of MCP-1, IP-10, IL-8, and VEGF were higher in the eyes of diabetic patients than in the eyes 
of non-diabetic subjects. The aqueous levels of MCP-1 and IP-10 were elevated in the eyes 
with severe NPDR and PDR compared to eyes with less severe DR and eyes of non-diabetic 
subjects  (Oh et al., 2010).  
7. Matrix metalloproteinases (MMPs) and metalloproteinase inhibitors (TIMP) 
7.1 Metalloproteinases (MMPs) 
Increased levels of metalloproteinases such as MMP-2, MMP-9 and MMP-14 have been 
demonstrated in early stages of retinopathy (Giebel et al., 2005). It has been demonstrated 
that high glucose increases the production of MMP-9 in retina cells (Kovluru et al., 2010; 
Mohammad & Kowluru, 2011). Increased level of MMPs leads to faster degradation of 
basement membrane proteins thereby increasing permeability. Pericyte apoptosis and 
basement membrane changes result in dilatation of capillaries and formation of 
microaneurisms. These conditions impair blood flow and in consequence lead to ischaemia 
in the retina. Disruption of physiological blood-retina barrier leads to formation of hard 
exudates. Retinal hypoxia worsens abnormalities in MMP/TIMP system caused by 
hyperglycaemia leading to excessive production of basement membrane material and 
proliferation of pathological capillaries. During retinal hypoxia the production of growth 
factors including VEGF increases, which stimulates metalloproteinases expression in 
extracellular matrix. It has been noted that in proliferative retinopathy the MMP-2 and 
MMP-9 activity increases (Jacqueminet et al., 2006, Kowluru et al., 2010). 
7.2 Tissue inhibitor of matrix metalloproteinase 3 (TIMP-3) 
Tissue inhibitor of matrix metalloproteinase 3 (TIMP-3) belongs to zinc (Zn) binding 
endopeptidases group which takes  part in remodelling and degradation of extracellular 
matrix. In the eye TIMP-3 is closely related to Bruch’s  membrane and regulates angiogenesis 
(Janssen et al., 2008). Analysis of micromatrix demonstrated that out of investigated 
metalloproteinases and its inhibitors: MMP1, MMP2, MMP11, MMP14, MMP25, TIMP1, 
TIMP2, TIMP3 and TIMP4 which were present in pericytes, only TIMIP3 mRNA may play role 
in impairment of microcirculation in diabetic retinopathy (Barth et al., 2007). 
8. Conclusion 
In developed countries diabetic retinopathy has become the most prevalent cause of 
blindness and loss of visual acuity, and its incidence is on the rise. Occurrence and 
progression of diabetic retinopathy may be a result of activation of immunological cells in 
the metabolic imbalance of the disease. Late diabetic complications may also reflect the 
ongoing autoimmunological process that started already in the prediabetic period. It has been 
proved that plasma levels of pro-inflammatory/pro-angiogenic factors was higher in 
patients with proliferative retinopathy than in those with diabetes but without 
morphological changes in the eye fundus. Moreover, high concentrations of VEGF, TNF-ǂ, 
IL-6 has been found not only in plasma but also in the vitreous of PDR patients. High hopes 
have been placed on the use of monoclonal antibodies anti-VEGF and anti-TNF. Particularly 
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etanercept, bevacizumab and ranibizumab have been used to prevent ocular 
neovascularisation. However only concomitant use of several therapeutic methods is 
regarded as effective in achieving plausible results in treatment of proliferative retinopathy. 
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